CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/20/2018
Start Date:March 29, 2018
End Date:September 2020
Contact:Beth Gudeman
Email:bethg@cba-1.com
Phone:859-266-5757

Use our guide to learn which trials are right for you!

A Phase I Trial of CBT-1® in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin

This study evaluates the combination of CBT-1® and doxorubicin for the treatment of
metastatic, unresectable sarcoma in patients who have progressed after treatment with
150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day
cycle, as well as doxorubicin on days 5 and 6.


Inclusion Criteria:

- Age ≥ 18 years

- Locally advanced or metastatic, unresectable sarcoma that has progressed after
treatment with 150 mg/m2 or less of doxorubicin or anthracycline equivalent

- Measurable disease by RECIST 1.1

- ECOG performance status of ≤ 1

- Life expectancy of > 3 months

- Able to swallow pills

- Adequate bone marrow and organ function as defined as:

- Hemoglobin > 9 g/dl

- Absolute neutrophil count ≥ 1,500/mcL

- Platelets ≥ 100,000/mcL

- Total bilirubin < 1.5 X ULN

- AST(SGOT)/ALT(SGPT) ≤3 X ULN (including patients with liver metastases)

- Creatinine <1.5 X ULN

- Cardiac ejection fraction >50% (by echocardiogram or MUGA) within 15 days of
enrollment

- Women of childbearing potential must have a negative serum or urine pregnancy test
within 7 days prior to enrollment.

- Participants must be willing and able to comply with the study scheduled visits,
laboratory tests, and other procedures outlined in the protocol.

- Pre-menopausal women must have a negative pregnancy test before study entry. Both
women and men must agree to use a medically acceptable method of contraception
throughout the treatment period and for at least six weeks after treatment
discontinuation. Acceptable methods of contraception include intrauterine device
(IUD), oral contraceptive, subdermal implant, double barrier and/or complete
abstinence (non-periodic).

- Washout period prior to Day 1 Cycle 1:

- 3 weeks since last chemotherapy or therapeutic radiation therapy

- 4 weeks or 3 half-lives since prior antibody-based therapy, whichever is shorter

- 2 weeks since any oral anti-neoplastic or oral investigational agent

- Resolution of treatment-related toxicity to < grade 1; alopecia and cutaneous toxicity
are allowed < grade 2

- >1 week since palliative RT

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Prior exposure to CBT-1

- Previously untreated sarcomas

- Low-grade sarcomas as well as alveolar soft parts sarcoma, clear cell sarcoma,
extraskeletal myxoid chondrosarcoma, well-differentiated liposarcoma, gastrointestinal
stromal tumor, chordoma

- Participants receiving other investigational agents

- Participants with known uncontrolled brain metastases

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, chronic indwelling drains, history of interstitial pneumonitis or
pulmonary fibrosis or psychiatric illness/social situations that would limit
compliance with study requirements

- Actively breastfeeding women unless it is interrupted during treatment and at least 6
weeks after treatment discontinuation
We found this trial at
5
sites
Santa Monica, California 90403
Principal Investigator: Sant P. Chawla, M.D.
Phone: 310-552-9999
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Gregory Cote, M.D., Ph.D.
Phone: 617-643-1770
?
mi
from
Boston, MA
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Principal Investigator: Steven Attia, D.O.
Phone: 904-953-3321
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Katherine Thornton, M.D.
Phone: 617-632-5204
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Principal Investigator: Melissa Burgess, M.D.
Phone: 412-864-7863
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials